Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 19/20 | 0.68 |
| ▸ | DRD3 | P35462 | 13/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | DRD4 | P21917 | 3/20 | 0.54 |
| ▸ | HTR2A | P28223 | 5/20 | 0.54 |
| ▸ | HTR1A | P08908 | 4/20 | 0.54 |
| ▸ | HTR7 | P34969 | 4/20 | 0.54 |
| ▸ | HTR6 | P50406 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30065991 | 0.92 | DRD2 (0.79) | DRD2DRD3SLC6A2SLC6A4DRD4 | |
| SCHEMBL22302317 | 0.92 | DRD2 (0.79) | DRD2DRD3SLC6A2SLC6A4DRD4 | |
| SCHEMBL22302309 | 0.92 | DRD2 (0.79) | DRD2DRD3SLC6A2SLC6A4DRD4 | |
| SCHEMBL23330962 | 0.92 | DRD2 (0.79) | DRD2DRD3SLC6A2SLC6A4DRD4 | |
| SCHEMBL30579548 | 0.92 | DRD2 (0.79) | DRD2DRD3SLC6A2SLC6A4DRD4 | |
| Hydrochloric Acid SCHEMBL28474663 | 0.91 | DRD2 (0.77) | DRD2DRD3SLC6A2SLC6A4DRD4 | |
| SCHEMBL30855285 | 0.81 | DRD2 (0.64) | DRD2DRD3SLC6A2SLC6A4DRD4 | |
| SCHEMBL20672353 | 0.81 | DRD2 (1.00) | DRD2DRD3SLC6A4DRD4HTR2A | |
| SCHEMBL1310960 | 0.81 | DRD2 (1.00) | DRD2DRD3SLC6A4DRD4HTR2A | |
| SCHEMBL2034152 | 0.81 | DRD2 (1.00) | DRD2DRD3SLC6A4DRD4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230076435-A1 | MODIFIER OF FOUR-MEMBERED RING DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230076435-A1 | MODIFIER OF FOUR-MEMBERED RING DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | GRM4, GRM5, GRIA4 | DRD2 343/4885DRD3 367/4885SLC6A2 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.